



Enalare Therapeutics to Present at BioNJ's Twelfth Annual BioPartnering Conference

PRINCETON, N.J., May 2, 2022 (Newswire.com) - Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, announced today that Herm Cukier, President and Chief Executive Officer, will be presenting at the BioNJ's Twelfth Annual BioPartnering Conference. The conference will run virtually from May 9th to the 13th, with Mr. Cukier's presentation recorded and played for all registered participants of the conference during the in-person networking event on May 9th. In addition, Enalare's Chief Operating Officer, Daniel Motto, will be taking questions after the presentation and meeting with potential investors and strategic partners.

About ENA-001

Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity designed as an agnostic respiratory stimulant. The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The compound utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in five human studies.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including post-surgery respiratory depression, drug overdose, and apnea of prematurity. The Company is planning to initiate additional clinical studies for ENA-001 across multiple indications in the coming years.

###

Contact:

Morgan Wagner

Enalare Investor Relations

Mwagner@enalare.com